ichorbio supplies two antibodies targeting PD-L2.
PD-L1 in vivo Antibodies
ichorbio supplies two low endotoxin antibodies to PD-L2 – clone TY25 for anti-mouse PD-L2 and clone 3.2 for anti-human PD-L2.
Background to PD-L2
Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10).
The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy.
ichorbio supplies a range of products related to PD-1 including low endotoxin antibodies, biosimilar antibodies, conjugated antibodies and recombinant proteins.